Adoptive Immunotherapy with Cl-IB-MECA-Treated CD8+ T Cells Reduces Melanoma Growth in Mice

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Montinaro, Antonella ^a   Forte, Giovanni ^a   Sorrentino, Rosalinda ^a   Luciano, Antonio ^b   Palma, Giuseppe ^b   Arra, Claudio ^b   Adcock, Ian M ^c   Pinto, Aldo ^a   Morello, Silvana ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; LANGERIN CELL; LYMPHOCYTE ACTIVATION; MELANOMA; MOUSE; NONHUMAN; SERODIAGNOSIS; SINGLE DRUG DOSE; TH1 CELL; TUMOR MICROENVIRONMENT;

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; MICE; MICE, INBRED C57BL;

MUS;

EID: 84866719355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045401     Document Type: Article

References (35)

1. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, et al. (2006) Cutaneous malignant melanoma. Mayo Clin Proc 81: 500-507.
2. Gray-Schopfer V, Wellbrock C, Marais R, (2007) Melanoma biology and new targeted therapy. Nature 445: 851-857.
3. Soengas MS, Lowe SW, (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3152.
4. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP, (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383-393.
5. Fang L, Lonsdorf AS, Hwang ST, (2008) Immunotherapy for advanced melanoma. J Invest Dermatol 128: 2596-2605.
6. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME, (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
7. Rosenberg SA, Dudley ME, (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240.
8. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, et al. (2010) CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16: 6122-6131.
9. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, et al. (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16: 2646-2655.
10. Stagg J, Smyth MJ, (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29: 5346-5358.
11. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J, (2001) International Union of Pharmacology XXV. Nomenclature and classification of adenosine receptors. Pharmacol Res 53: 527-552.
12. Junger WG, (2011) Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 11: 201-212.
13. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, et al. (2006) A2A adenosine receptor protects tumours from antitumour T cells. Proc Natl Acad Sci USA 103: 13132-13137.
14. Raskovolova T, Lokshin A, Huang X, Su Y, Mandic M, et al. (2007) Inhibition of cytokine production and cytotoxic activity oh human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signalling. Cancer Res 67: 5949-5956.
15. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, et al. (2008) A2A receptor signalling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111: 251-259.
16. Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, et al. (2009) A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol 183: 5487-5543.
17. Kamkumar V, Stiles GL, Beaven MA, Ali H, (1993) The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 268: 16887-16890.
18. Harish A, Hohana G, Fishman P, Arnon O, Bar-Yehuda S, (2003) A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 23: 1245-1249.
19. Morello S, Sorrentino R, Montinaro A, Luciano A, Maiolino P, et al. (2011) NK1.1 cells and CD8 T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model. Neoplasia 13: 365-373.
20. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, et al. (1992) Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 127: 5-24.
21. Fishman P, Bar-Yehuda MS, Synowitz M, Powell JP, Klotz KN, et al. (2009). Adenosine receptors and cancer. In Adenosine receptors in health and disease, Handbook of experimental Pharmacology, eds Wilson CN and Mustafa SJ (Springer-Verlag Berlin Heidelberg) p 399-441.
22. Suk K, Chang I, Kim YH, Kim S, Kim JY, et al. (2001) Interferon gamma (IFN gamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFN gamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. J Biol Chem 276: 13153-13159.
23. Dunn GP, Koebel CM, Schreiber RD, (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848.
24. Eberle J, Fecker LF, Forschner T, Ulrich C, Röwert-Huber J, et al. (2007) Apoptosis pathways as promising targets for skin cancer therapy. Br J Dermatol 156 Suppl 3: 18-24.
25. Dobrzanski MJ, Reome JB, Dutton RW, (2001) Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8effector cell-mediated tumor rejection. Clin Immunol 98: 70-84.
26. Prévost-Blondel A, Neuenhahn M, Rawiel M, Pircher H, (2000) Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen. Eur J Immunol 30: 2507-2515.
27. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626.
28. Macgregor JN, Li Q, Chang AE, Braun TM, Hughes DP, et al. (2006) Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin. Cancer Res 66: 4913-4921.
29. Dace DS, Chen PW, Niederkorn JY, (2007) CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism. J Immunol 178: 6115-6122.
30. Poehlein CH, Hu HM, Yamada J, Assmann I, Alvord WG, et al. (2003) TNF plays an essential role in tumor regression after adoptive transfer ofperforin/IFN-gamma double knockout effector T cells. J Immunol 170: 2004-2013.
31. Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, et al. (2002) Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 168: 3484-3492.
32. Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, et al. (2000) T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol 165: 7116-7124.
33. Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, et al. (2007) TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 117: 3833-3845.
34. Stoitzer P, Sparben F, Tripp CH, (2010) Langerhans cells as targets for immunotherapy against skin cancer. Immunol Cell Biol 88: 431-437.
35. Trevejo JM, Marino MW, Philpott N, Josien R, Richards EC, et al. (2001) TNF-α-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci USA 98: 12162-12167.